What is William Blair's Forecast for APLS Q1 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Equities research analysts at William Blair issued their Q1 2025 earnings estimates for Apellis Pharmaceuticals in a note issued to investors on Monday, October 28th. William Blair analyst L. Hanbury-Brown anticipates that the company will post earnings of ($0.09) per share for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.37) per share. William Blair also issued estimates for Apellis Pharmaceuticals' Q2 2025 earnings at $0.06 EPS and Q3 2025 earnings at $0.13 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.03. The company had revenue of $199.70 million during the quarter, compared to the consensus estimate of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The firm's quarterly revenue was up 110.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.02) earnings per share.

Several other analysts also recently weighed in on APLS. HC Wainwright reduced their price objective on shares of Apellis Pharmaceuticals from $92.00 to $83.00 and set a "buy" rating for the company in a research report on Friday, August 2nd. Wedbush boosted their price objective on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the stock a "neutral" rating in a research report on Friday, August 9th. Needham & Company LLC restated a "buy" rating and set a $85.00 price objective on shares of Apellis Pharmaceuticals in a research report on Friday, September 20th. Jefferies Financial Group restated a "buy" rating and set a $80.00 price objective on shares of Apellis Pharmaceuticals in a research report on Wednesday, July 31st. Finally, Robert W. Baird reduced their price objective on shares of Apellis Pharmaceuticals from $96.00 to $92.00 and set an "outperform" rating for the company in a research report on Monday, September 23rd. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $65.41.

Apellis Pharmaceuticals Stock Down 1.6 %

Shares of NASDAQ:APLS traded down $0.45 during trading on Thursday, hitting $27.26. 1,664,838 shares of the company were exchanged, compared to its average volume of 1,686,597. The stock has a market capitalization of $3.31 billion, a P/E ratio of -7.88 and a beta of 0.87. The company has a debt-to-equity ratio of 1.73, a current ratio of 5.08 and a quick ratio of 4.18. Apellis Pharmaceuticals has a 12-month low of $26.28 and a 12-month high of $73.80. The firm's 50 day moving average price is $32.52 and its 200-day moving average price is $37.94.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the company's stock in a transaction on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the transaction, the director now owns 100,000 shares in the company, valued at approximately $3,623,000. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of large investors have recently made changes to their positions in APLS. Assenagon Asset Management S.A. increased its holdings in shares of Apellis Pharmaceuticals by 191.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company's stock valued at $61,845,000 after purchasing an additional 1,409,707 shares in the last quarter. Iron Triangle Partners LP purchased a new position in shares of Apellis Pharmaceuticals in the 1st quarter valued at about $32,329,000. Fiera Capital Corp increased its holdings in shares of Apellis Pharmaceuticals by 47.7% in the 2nd quarter. Fiera Capital Corp now owns 1,401,190 shares of the company's stock valued at $53,750,000 after purchasing an additional 452,753 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Apellis Pharmaceuticals by 337.3% in the 2nd quarter. AQR Capital Management LLC now owns 246,880 shares of the company's stock valued at $9,177,000 after purchasing an additional 190,420 shares in the last quarter. Finally, Redmile Group LLC purchased a new position in shares of Apellis Pharmaceuticals in the 1st quarter valued at about $9,111,000. Hedge funds and other institutional investors own 96.29% of the company's stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).